Eosinophilic Granulomatosis With Polyangiitis Treatment Market Report 2026

The eosinophilic granulomatosis with polyangiitis treatment market size has grown strongly in recent years. It will grow from $1.41 billion in 2025 to $1.54 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to autoimmune disease awareness, corticosteroid reliance, rare disease diagnosis improvements, hospital-based immunology care, inflammation management needs.

The eosinophilic granulomatosis with polyangiitis treatment market size is expected to see strong growth in the next few years. It will grow to $2.22 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to biologic drug innovation, rare disease funding support, personalized autoimmune treatment, specialty clinic growth, early intervention protocols. Major trends in the forecast period include rising use of targeted biologic therapies, increased focus on rare autoimmune diseases, growth in long-term immunosuppressive treatment, expansion of specialty autoimmune care, emphasis on early disease control.

The rising incidence of asthma among the elderly is expected to drive the growth of the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market in the coming years. Asthma is a respiratory condition characterized by swelling and narrowing of the airways, making breathing difficult. Among older adults, the incidence of asthma is increasing due to declining lung function. As lungs lose elasticity and airway muscles weaken with age, breathing becomes more challenging, making the elderly more susceptible to inflammation and respiratory conditions. The higher prevalence of asthma in this population results in more cases being evaluated for related conditions such as eosinophilic granulomatosis with polyangiitis, which often begins with asthma, thereby increasing demand for treatment. For example, in 2024, the Global Initiative for Asthma, a US-based medical organization, reported that asthma affects over 260 million people worldwide and causes more than 450,000 deaths annually. Therefore, the rising prevalence of asthma among older adults is driving the growth of the EGPA treatment market.

The increasing prevalence of allergic reactions is expected to propel growth in the eosinophilic granulomatosis with polyangiitis treatment market. Allergic reactions are becoming more common due to rising air pollution, as pollutants like smoke, dust, and chemicals can irritate the immune system and increase sensitivity to allergens. As allergic reactions increase, more individuals develop conditions linked to immune system overactivity, such as eosinophilic granulomatosis with polyangiitis, driving demand for effective treatments to manage inflammation and associated symptoms. For instance, in 2024, PubMed, citing the US-based National Institutes of Health, reported that the most common allergic comorbidities among patients with food allergies were atopic dermatitis (48%), asthma (46%), and allergic rhinitis (39%). Many patients experienced more than one food-related allergic reaction per year (42%), with 46% experiencing food-induced anaphylaxis. Therefore, the rising prevalence of allergic reactions is contributing to the growth of the EGPA treatment market.

Key companies in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market are conducting clinical trials to evaluate the safety and efficacy of both new and existing therapies. Clinical trials aim to improve treatment options, gain regulatory approvals, and enhance patient care. For example, in September 2024, AstraZeneca, a UK-based pharmaceutical and biotechnology company, reported positive outcomes from the MANDARA Phase III trial. The trial demonstrated that Fasenra (benralizumab) is effective in inducing remission in patients with eosinophilic granulomatosis with polyangiitis. Results showed that benralizumab achieved remission rates comparable to mepolizumab while reducing the need for oral glucocorticoids. This represents an important advancement toward more targeted, steroid-sparing treatment approaches for eosinophilic granulomatosis with polyangiitis.

Major companies operating in the eosinophilic granulomatosis with polyangiitis treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Roche Holding AG, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Intas Pharmaceuticals, Mylan N.V., Astellas Pharma Inc., Biogen Inc., Fresenius Kabi, Amgen Inc., Sun Pharmaceutical Industries, Apotex Inc., Cipla Ltd., Dr. Reddy’s Laboratories, Lupin Limited, Alkem Laboratories, NS Pharma.

North America was the largest region in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic granulomatosis with polyangiitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the eosinophilic granulomatosis with polyangiitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the eosinophilic granulomatosis with polyangiitis treatment market by increasing costs of imported biologics, immunoglobulins, and specialty drugs. Hospitals and specialty clinics in developed regions are most affected due to reliance on imported therapies. These tariffs raise treatment costs by increasing expenses for rare disease management and long-term immunotherapy. However, they support domestic biologic manufacturing, strengthening regional capabilities for complex therapies.

The eosinophilic granulomatosis with polyangiitis treatment market research report is one of a series of new reports that provides eosinophilic granulomatosis with polyangiitis treatment market statistics, including eosinophilic granulomatosis with polyangiitis treatment industry global market size, regional shares, competitors with a eosinophilic granulomatosis with polyangiitis treatment market share, detailed eosinophilic granulomatosis with polyangiitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the eosinophilic granulomatosis with polyangiitis treatment industry. This eosinophilic granulomatosis with polyangiitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Eosinophilic granulomatosis with polyangiitis (EGPA) treatment involves medical strategies aimed at managing this rare autoimmune disorder, which causes inflammation in small blood vessels. The treatment is designed to reduce inflammation, control symptoms, and prevent disease progression.

The main drug classes in the EGPA treatment market include steroids, immunosuppressants, biologics, and immune globulins. Steroids are organic compounds, including natural hormones and synthetic drugs, that possess anti-inflammatory and immunosuppressive effects. They can be administered via multiple routes, such as oral, intravenous, and intramuscular. Distribution channels for these treatments include online pharmacies, hospital pharmacies, drug stores, and retail pharmacies, while the primary end users are hospitals, clinics, and home healthcare providers.

The eosinophilic granulomatosis with polyangiitis treatment market consists of sales of azathioprine, corticosteroids, methotrexate, and monoclonal antibodies such as mepolizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.